Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra LifeSciences Holdings Corporation (Nasdaq: IART) is frequently featured in healthcare and capital markets news as a global medical technology company focused on neurosurgery, tissue reconstruction, and regenerative care. Its news flow, as reflected in recent press releases, spans financial results, regulatory milestones, clinical technology updates, policy developments, and investor conference participation.
Investors following IART news will see regular quarterly earnings announcements, typically accompanied by detailed segment commentary for Codman Specialty Surgical and Tissue Technologies, as well as discussions of organic revenue trends, adjusted profitability metrics, and management’s outlook. These releases are often paired with notices of conference calls and webcasts accessible through the company’s investor relations channels.
Beyond financial reporting, Integra issues news on regulatory and clinical developments. Recent examples include FDA 510(k) clearance for expanded use of the CUSA Clarity Ultrasonic Surgical Aspirator System in cardiac surgery and updates on neurosurgical technologies such as CereLink, Aurora, Mayfield devices, and Durepair Dura Regeneration Matrix. The company also highlights its presence at major clinical meetings, including the Congress of Neurological Surgeons Annual Meeting, where it showcases its neurosurgical portfolio.
Policy and reimbursement developments are another theme in Integra’s news. The company has commented on CMS rules affecting Medicare beneficiary access to skin substitutes, noting the inclusion of its dermal regenerative templates, decellularized dermal scaffolds, and amniotic tissue membranes, as well as specific brands like Integra matrices, PriMatrix, Cytal, and AmnioExcel.
In addition, IART news covers leadership and governance updates, such as the appointment of a chief medical officer and participation by senior executives in investor healthcare conferences. For readers and investors, the IART news page offers a centralized view of Integra’s financial performance, product and regulatory milestones, policy environment, and corporate developments.
Integra LifeSciences Holdings Corporation (Nasdaq: IART) has appointed Renee Lo as an independent director, effective July 18, 2022. Lo brings significant experience in digital transformation from her role at Microsoft, where she leads data and AI business in Asia. She has a background at Amazon Web Services and extensive experience in the technology sector, holding leadership roles in product development and corporate strategy. This addition aims to enhance the board's capability in delivering shareholder value.
Integra LifeSciences (NASDAQ: IART) will release its second quarter 2022 financial results on July 27, 2022, before the market opens. Following the release, management will hold a conference call at 8:30 a.m. ET, accessible by calling 800-289-0720 with the passcode 2688312. A webcast of the call will also be available on their website, with a replay accessible until August 7, 2022. Integra specializes in regenerative tissue technologies and offers a broad portfolio of recognized brands aimed at enhancing patient care.
On May 11, 2022, Hilco Redevelopment Partners announced that Integra LifeSciences (IART) will occupy 100,000 square feet of newly redeveloped space at 400 Wood Road in Braintree, MA. This facility will manufacture surgical reconstruction devices, contributing significantly to local job creation with at least 150 new positions. The Braintree Town Council approved a tax increment financing (TIF) agreement to support this development. Integra plans to achieve full occupancy by late 2025, aiming to positively impact the local economy.
Integra LifeSciences Holdings Corporation (IART) reported Q1 2022 revenues of $376.6 million, a 4.6% increase year-over-year. GAAP earnings per diluted share declined to $0.39 from $0.53 in Q1 2021, while adjusted EPS rose to $0.74 from $0.69. The company raised its 2022 organic growth guidance from 3.5%-5% to 3.8%-5.2% and reaffirmed total revenue growth at 2.5%-3.5%. The gross margin improved to 62.1%. Cash flow from operations was $44 million, with net debt of $1.15 billion.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced it will release its first quarter 2022 financial results on April 27, 2022, before the market opens. The management team will host a conference call at 8:30 a.m. ET to discuss the results. Interested parties can access the call by dialing (800)-289-0720 or via a live webcast on the company’s website. A replay will be available until May 7, 2022. Integra specializes in regenerative tissue technologies and neurosurgical solutions, offering a diverse range of high-quality brands.
Integra LifeSciences (Nasdaq: IART) has launched the NeuraGen® 3D Nerve Guide Matrix, a resorbable implant designed to repair peripheral nerve discontinuities. This innovative product combines bovine type 1 collagen with a unique inner matrix featuring porous channels, promoting Schwann cell migration and axonal growth for enhanced recovery after mid-gap nerve repairs. With approximately 50,000 nerve repair procedures performed annually, NeuraGen 3D aims to improve patient outcomes. The launch represents a significant advancement in Integra's peripheral nerve repair portfolio.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported its Q4 2021 and full-year results on February 23, 2022. Q4 revenues reached $405.5 million, up 4.3% year-over-year, with GAAP EPS at $0.53, down from $1.09 in Q4 2020. For the full year, revenues were $1,542.4 million, a 12.4% increase, with GAAP EPS rising to $1.98 from $1.57. The company provided 2022 guidance, projecting revenue growth of 2.5% to 3.5% and adjusted EPS between $3.27 and $3.35.
Integra LifeSciences (IART) announced preliminary revenue results for Q4 and full-year 2021, with Q4 revenue expected between $404 million and $406 million, marking a 4% increase year-over-year. Full-year revenue is projected at $1,541 million to $1,543 million, reflecting a 12% increase. The company plans a $125 million share repurchase under an existing $225 million authorization. CEO Jan De Witte expressed optimism about the company's growth strategies, including product launches and international expansion, reaffirming long-term organic growth targets of 5%-7%.
BD (Becton, Dickinson and Company) announced the formation of a nine-person board of directors for Embecta Corp., which will hold BD's Diabetes Care business after the planned spinoff. The board will be led by David F. Melcher and include notable members such as Claire Pomeroy and Christopher R. Reidy. Devdatt Kurdikar will serve as CEO of Embecta. The spinoff is expected to be completed in Q2 2022, pending regulatory approvals. The governance structure includes various committees, and directors will serve staggered terms.
Integra LifeSciences (NASDAQ: IART) reported Q3 2021 revenues of $386.9 million, up 4.5% year-over-year. GAAP diluted EPS increased to $0.51 from $0.38 in 2020, while adjusted EPS rose to $0.86 from $0.80. The company reaffirmed its 2021 revenue guidance of $1,540 million to $1,550 million and raised adjusted EPS guidance to $3.16-$3.20. Cash flow from operations hit $82.8 million, a 18.9% increase. Despite challenges, including COVID-related impacts, Integra showed strong performance in its Codman Specialty Surgical segment, buoyed by new product launches like the CereLink ICP monitor.